Causal association of circulating immune cells and lymphoma: A Mendelian randomization study
Author:
Wang Feixiang1, Huang Guoxin2, Luo Yuqing1, Xiong Kaixin1, Liu Ying3, Wang Yao4
Affiliation:
1. Medical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , Guangdong , Guangzhou , 510095 , China 2. Department of Evidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine , Xiangyang , Hubei, 441000 , China 3. Department of Evidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine , No. 15, Jiefang Road, Xiangyang , Hubei, 441000 , China 4. Medical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , No. 78, Hengzhigang, Yuexiu District, Guangdong , Guangzhou , 510095 , China
Abstract
Abstract
Background
Malignant lymphoma (ML) is a group of malignant tumors originating from the lymphatic hematopoietic system. Previous studies have found a correlation between circulating immune cells and ML. Nonetheless, the precise influence of circulating immune cells on ML remains uncertain.
Methods
Based on publicly available genetic data, we explored causal associations between 731 immune cell signatures and ML risk. A total of four types of immune signatures, median fluorescence intensities, relative cell, absolute cell, and morphological parameters were included. Primary analysis was performed using inverse variance weighting (IVW) to assess the causal relationship between circulating immune cells and the risk of ML. Sensitivity analysis was conducted using Cochran’s Q test, the Mendelian randomization Egger regression intercept test, and leave-one-out analysis.
Results
ML had a statistically significant effect on immunophenotypes. Twenty-three immunophenotypes were identified to be significantly associated with Hodgkin lymphoma risk through the IVW approach, and the odds ratio values of CD64 on CD14− CD16+ monocyte [2.31, 95% confidence interval (CI) = 1.41–3.79, P1 = 0.001], IgD+ CD24+ B-cell %lymphocyte (2.06, 95% CI = 1.13–3.79, P1 = 0.018), B-cell %lymphocyte (1.94, 95% CI = 1.08–3.50, P1 = 0.027), CD24+ CD27+ B-cell %lymphocyte (1.68, 95% CI = 1.03–2.74, P1 = 0.039), and CD14+ CD16− monocyte %monocyte (1.60, 95% CI = 1.15–2.24, P1 = 0.006) ranked in the top five. Eleven immunophenotypes were identified to be significantly associated with non-Hodgkin lymphoma risk, CD86 on granulocyte (2.35, 95% CI = 1.18–4.69, P1 = 0.015), CD28−CD8+ T-cell absolute count (1.76, 95% CI = 1.03–2.99, P1 = 0.036), CCR2 on myeloid dendritic cell (CD24+ CD27+ B cell, 95% CI = 1.02–1.66, P1 = 0.034), CD3 on effector memory CD8+ T cell (1.29, 95% CI = 1.02–1.64, P1 = 0.012), and natural killer T %lymphocyte (1.28, 95% CI = 1.01–1.62, P1 = 0.046) were ranked in the top five.
Conclusion
This study presents compelling evidence indicating the correlation between circulating immune cells and lymphoma, thus providing guidance for future clinical research.
Publisher
Walter de Gruyter GmbH
Reference43 articles.
1. Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, et al. Advances in targeted therapy for malignant lymphoma. Sig Transduct Target Ther. 2020 Mar;5(1):15. 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021 May;71(3):209–49. 3. Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017 Jun;12(3):217–26. 4. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021 Mar;12:636568. 5. Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 2019 Dec;77:105999.
|
|